Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

The company's capital structure is characterized by a low debt-to-equity ratio of 0.1, indicating a conservative leverage profile. Its liquidity position is assessed as medium, with a current ratio of 3.89, suggesting the company can cover short-term obligations but may face constraints in more volatile environments. The price-to-book ratio of 1.93 and price-to-tangible-book ratio of 1.93 suggest the market values the company at a moderate premium to its book value. The enterprise value to EBITDA ratio of 99.12 and enterprise value to revenue ratio of 13.0 indicate a high valuation relative to earnings and revenue, which may reflect market expectations of future growth or sector-specific dynamics.

Profitability metrics show a return on equity (ROE) of 1.81% and return on assets (ROA) of 1.28%, both below the typical thresholds for high-performing pharmaceutical firms. The net profit margin is 11.62% (28.51 million CNY net income on 245.24 million CNY revenue), which is relatively low compared to industry benchmarks. The gross margin of 61.61% (151.09 million CNY gross profit on 245.24 million CNY revenue) is strong, but the operating margin of 13.11% (32.17 million CNY operating income on 245.24 million CNY revenue) suggests significant operating expenses are eroding profitability.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks, particularly in the Chinese pharmaceutical market. The absence of segment-specific revenue data limits the ability to assess the performance of individual product lines or therapeutic areas.

The company's growth trajectory is uncertain, with no disclosed revenue growth rates or forward-looking guidance. The capital expenditure of -41.56 million CNY suggests a reduction in investment, which may indicate a focus on cost control or a strategic shift in resource allocation. The outlook for the current fiscal year and the next fiscal year is not provided, making it difficult to assess the company's growth potential.

The risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates potential liquidity constraints. The dilution risk is low, with no near-term pressure from share issuance or convertible instruments. The company's conservative leverage and strong equity base provide some buffer against financial distress, but the high valuation multiples suggest investors are pricing in future growth that may not materialize.

Recent events and filings do not provide specific details on strategic initiatives, product launches, or regulatory developments. The absence of recent transcripts or filings limits the ability to assess the company's operational and strategic direction. Investors should monitor the company's ability to maintain profitability and manage its capital structure effectively in a competitive and regulated industry.

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (002864.SZ) has undergone a significant update to its risk and classification profile, with the most material changes being the formal assignment of its economic sector and activity taxonomy. The company is now explicitly classified within the Healthcare sector, with its primary activity identified as Pharmaceuticals. This categorization, marked with medium severity in the recent analysis, provides a clearer structural definition of the firm’s operational focus, distinguishing it from broader or undefined industrial classifications. Alongside these taxonomic updates, the company’s risk assessment framework has been populated with specific metrics where none previously existed. The dilution risk has been assessed as "low," indicating a stable capital structure with minimal immediate threat of share value erosion through new issuance. This low-severity assessment suggests that current equity dynamics are not under pressure from aggressive financing activities that would typically trigger higher dilution concerns. Conversely, the liquidity risk has been classified as "medium," also at a low severity level. This new field indicates that while the company maintains adequate short-term financial flexibility, there are moderate considerations regarding cash flow or asset convertibility that warrant monitoring. The transition from no prior value to a defined "medium" status highlights an area of financial health that is neither critical nor negligible, requiring balanced oversight. These four tracked-field changes collectively refine the analytical view of Shaanxi Panlong Pharmaceutical, moving from an undefined state to a structured profile within the Healthcare sector. With no analyst coverage, index memberships, or top holder data currently recorded in the company overview, these internal risk and classification metrics serve as the primary indicators of the firm’s current financial posture. The updates underscore a low dilution environment but a moderate liquidity context, offering investors a more nuanced baseline for evaluating the company’s stability. [doc:002864.sz-ha-financials]

Cash conversion ratio of 3.9 is best-in-class compared to the cohort median of 0.95, ensuring robust liquidity.

Revenue grew 17.1% year-over-year to CNY 1.14 billion, showing strong top-line expansion despite profit pressures.

Debt-to-equity ratio of 0.1 is below the cohort median of 0.18, reflecting a conservative capital structure.

The company faces high credit risk, which could impair financial stability and increase borrowing costs.

Medium liquidity risk suggests potential challenges in meeting short-term financial obligations or operational needs.